My experience with any CR is that retail investors see the number as what the "Company" values their shares at, and as a result there is a dip to that number short term.
I'm just glad it wasn't an offer to retail investors in large numbers, and the number on offer is below 50 Million.
As a result, we're debt free and cashed up to the end of phase one for both drugs at which point we'll be monetarizing any positive results.
My experience with any CR is that retail investors see the...
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
